Selected research
Market Analysis & Forecast
Global Follicular Lymphoma Drugs Market Analysis and Forecast 2026-2032
Market perspective
The global Follicular Lymphoma Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for Follicular Lymphoma Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Europe market for Follicular Lymphoma Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Read the full market overview
Asia-Pacific market for Follicular Lymphoma Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The China market for Follicular Lymphoma Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The major global companies of Follicular Lymphoma Drugs include Eisai, Teva, Novartis, Roche, Pfizer, FOSUNKite, Bayer, Beigene and Secura Bio, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Follicular Lymphoma Drugs, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.
This report researches the key producers of Follicular Lymphoma Drugs, also provides the revenue of main regions and countries. Of the upcoming market potential for Follicular Lymphoma Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Follicular Lymphoma Drugs revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Follicular Lymphoma Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Follicular Lymphoma Drugs revenue, projected growth trends, production technology, application and end-user industry.
Follicular Lymphoma Drugs Segment by Company
Eisai
Teva
Novartis
Roche
Pfizer
FOSUNKite
Bayer
Beigene
Secura Bio
MundiPharma
JW Therapeutics
Gilead Sciences
Epizyme
Eagle Pharmaceuticals
Bristol-Myers Squibb
Acrotech Biopharma
Follicular Lymphoma Drugs Segment by Type
Anti-CD20 mAbs
Kinase Inhibitor
Chemotherapy Agents
Others
Follicular Lymphoma Drugs Segment by Application
Injection
Oral
Follicular Lymphoma Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Follicular Lymphoma Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Follicular Lymphoma Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Follicular Lymphoma Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Follicular Lymphoma Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Follicular Lymphoma Drugs company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Follicular Lymphoma Drugs revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Anti-CD20 mAbs
- Kinase Inhibitor
- Chemotherapy Agents
- Others
Applications
- Injection
- Oral
Companies covered
- Eisai
- Teva
- Novartis
- Roche
- Pfizer
- FOSUNKite
- Bayer
- Beigene
- Secura Bio
- MundiPharma
- JW Therapeutics
- Gilead Sciences
- Epizyme
- Eagle Pharmaceuticals
- Bristol-Myers Squibb
- Acrotech Biopharma
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Follicular Lymphoma Drugs Market by Type
- 1.2.1 Global Follicular Lymphoma Drugs Market Size by Type, 2021 VS 2025 VS 2032
- 1.2.2 Anti-CD20 mAbs
- 1.2.3 Kinase Inhibitor
- 1.2.4 Chemotherapy Agents
- 1.2.5 Others
- 1.3 Follicular Lymphoma Drugs Market by Application
- 1.3.1 Global Follicular Lymphoma Drugs Market Size by Application, 2021 VS 2025 VS 2032
- 1.3.2 Injection
- 1.3.3 Oral
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Follicular Lymphoma Drugs Market Dynamics
- 2.1 Follicular Lymphoma Drugs Industry Trends
- 2.2 Follicular Lymphoma Drugs Industry Drivers
- 2.3 Follicular Lymphoma Drugs Industry Opportunities and Challenges
- 2.4 Follicular Lymphoma Drugs Industry Restraints
3 Global Growth Perspective
- 3.1 Global Follicular Lymphoma Drugs Market Perspective (2021-2032)
- 3.2 Global Follicular Lymphoma Drugs Growth Trends by Region
- 3.2.1 Global Follicular Lymphoma Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 3.2.2 Global Follicular Lymphoma Drugs Market Size by Region (2021-2026)
- 3.2.3 Global Follicular Lymphoma Drugs Market Size by Region (2027-2032)
4 Competitive Landscape by Players
- 4.1 Global Follicular Lymphoma Drugs Revenue by Players
- 4.1.1 Global Follicular Lymphoma Drugs Revenue by Players (2021-2026)
- 4.1.2 Global Follicular Lymphoma Drugs Revenue Market Share by Players (2021-2026)
- 4.1.3 Global Follicular Lymphoma Drugs Players Revenue Share Top 10 and Top 5 in 2025
- 4.2 Global Follicular Lymphoma Drugs Key Players Ranking, 2024 VS 2025 VS 2026
- 4.3 Global Follicular Lymphoma Drugs Key Players Headquarters & Area Served
- 4.4 Global Follicular Lymphoma Drugs Players, Product Type & Application
- 4.5 Global Follicular Lymphoma Drugs Players Establishment Date
- 4.6 Market Competitive Analysis
- 4.6.1 Global Follicular Lymphoma Drugs Market CR5 and HHI
- 4.6.3 2025 Follicular Lymphoma Drugs Tier 1, Tier 2, and Tier 3
5 Follicular Lymphoma Drugs Market Size by Type
- 5.1 Global Follicular Lymphoma Drugs Revenue by Type (2021 VS 2025 VS 2032)
- 5.2 Global Follicular Lymphoma Drugs Revenue by Type (2021-2032)
- 5.3 Global Follicular Lymphoma Drugs Revenue Market Share by Type (2021-2032)
6 Follicular Lymphoma Drugs Market Size by Application
- 6.1 Global Follicular Lymphoma Drugs Revenue by Application (2021 VS 2025 VS 2032)
- 6.2 Global Follicular Lymphoma Drugs Revenue by Application (2021-2032)
- 6.3 Global Follicular Lymphoma Drugs Revenue Market Share by Application (2021-2032)
7 Company Profiles
- 7.1 Eisai
- 7.1.1 Eisai Company Information
- 7.1.2 Eisai Business Overview
- 7.1.3 Eisai Follicular Lymphoma Drugs Revenue and Gross Margin (2021-2026)
- 7.1.4 Eisai Follicular Lymphoma Drugs Product Portfolio
- 7.1.5 Eisai Recent Developments
- 7.2 Teva
- 7.2.1 Teva Company Information
- 7.2.2 Teva Business Overview
- 7.2.3 Teva Follicular Lymphoma Drugs Revenue and Gross Margin (2021-2026)
- 7.2.4 Teva Follicular Lymphoma Drugs Product Portfolio
- 7.2.5 Teva Recent Developments
- 7.3 Novartis
- 7.3.1 Novartis Company Information
- 7.3.2 Novartis Business Overview
- 7.3.3 Novartis Follicular Lymphoma Drugs Revenue and Gross Margin (2021-2026)
- 7.3.4 Novartis Follicular Lymphoma Drugs Product Portfolio
- 7.3.5 Novartis Recent Developments
- 7.4 Roche
- 7.4.1 Roche Company Information
- 7.4.2 Roche Business Overview
- 7.4.3 Roche Follicular Lymphoma Drugs Revenue and Gross Margin (2021-2026)
- 7.4.4 Roche Follicular Lymphoma Drugs Product Portfolio
- 7.4.5 Roche Recent Developments
- 7.5 Pfizer
- 7.5.1 Pfizer Company Information
- 7.5.2 Pfizer Business Overview
- 7.5.3 Pfizer Follicular Lymphoma Drugs Revenue and Gross Margin (2021-2026)
- 7.5.4 Pfizer Follicular Lymphoma Drugs Product Portfolio
- 7.5.5 Pfizer Recent Developments
- 7.6 FOSUNKite
- 7.6.1 FOSUNKite Company Information
- 7.6.2 FOSUNKite Business Overview
- 7.6.3 FOSUNKite Follicular Lymphoma Drugs Revenue and Gross Margin (2021-2026)
- 7.6.4 FOSUNKite Follicular Lymphoma Drugs Product Portfolio
- 7.6.5 FOSUNKite Recent Developments
- 7.7 Bayer
- 7.7.1 Bayer Company Information
- 7.7.2 Bayer Business Overview
- 7.7.3 Bayer Follicular Lymphoma Drugs Revenue and Gross Margin (2021-2026)
- 7.7.4 Bayer Follicular Lymphoma Drugs Product Portfolio
- 7.7.5 Bayer Recent Developments
- 7.8 Beigene
- 7.8.1 Beigene Company Information
- 7.8.2 Beigene Business Overview
- 7.8.3 Beigene Follicular Lymphoma Drugs Revenue and Gross Margin (2021-2026)
- 7.8.4 Beigene Follicular Lymphoma Drugs Product Portfolio
- 7.8.5 Beigene Recent Developments
- 7.9 Secura Bio
- 7.9.1 Secura Bio Company Information
- 7.9.2 Secura Bio Business Overview
- 7.9.3 Secura Bio Follicular Lymphoma Drugs Revenue and Gross Margin (2021-2026)
- 7.9.4 Secura Bio Follicular Lymphoma Drugs Product Portfolio
- 7.9.5 Secura Bio Recent Developments
- 7.10 MundiPharma
- 7.10.1 MundiPharma Company Information
- 7.10.2 MundiPharma Business Overview
- 7.10.3 MundiPharma Follicular Lymphoma Drugs Revenue and Gross Margin (2021-2026)
- 7.10.4 MundiPharma Follicular Lymphoma Drugs Product Portfolio
- 7.10.5 MundiPharma Recent Developments
- 7.11 JW Therapeutics
- 7.11.1 JW Therapeutics Company Information
- 7.11.2 JW Therapeutics Business Overview
- 7.11.3 JW Therapeutics Follicular Lymphoma Drugs Revenue and Gross Margin (2021-2026)
- 7.11.4 JW Therapeutics Follicular Lymphoma Drugs Product Portfolio
- 7.11.5 JW Therapeutics Recent Developments
- 7.12 Gilead Sciences
- 7.12.1 Gilead Sciences Company Information
- 7.12.2 Gilead Sciences Business Overview
- 7.12.3 Gilead Sciences Follicular Lymphoma Drugs Revenue and Gross Margin (2021-2026)
- 7.12.4 Gilead Sciences Follicular Lymphoma Drugs Product Portfolio
- 7.12.5 Gilead Sciences Recent Developments
- 7.13 Epizyme
- 7.13.1 Epizyme Company Information
- 7.13.2 Epizyme Business Overview
- 7.13.3 Epizyme Follicular Lymphoma Drugs Revenue and Gross Margin (2021-2026)
- 7.13.4 Epizyme Follicular Lymphoma Drugs Product Portfolio
- 7.13.5 Epizyme Recent Developments
- 7.14 Eagle Pharmaceuticals
- 7.14.1 Eagle Pharmaceuticals Company Information
- 7.14.2 Eagle Pharmaceuticals Business Overview
- 7.14.3 Eagle Pharmaceuticals Follicular Lymphoma Drugs Revenue and Gross Margin (2021-2026)
- 7.14.4 Eagle Pharmaceuticals Follicular Lymphoma Drugs Product Portfolio
- 7.14.5 Eagle Pharmaceuticals Recent Developments
- 7.15 Bristol-Myers Squibb
- 7.15.1 Bristol-Myers Squibb Company Information
- 7.15.2 Bristol-Myers Squibb Business Overview
- 7.15.3 Bristol-Myers Squibb Follicular Lymphoma Drugs Revenue and Gross Margin (2021-2026)
- 7.15.4 Bristol-Myers Squibb Follicular Lymphoma Drugs Product Portfolio
- 7.15.5 Bristol-Myers Squibb Recent Developments
- 7.16 Acrotech Biopharma
- 7.16.1 Acrotech Biopharma Company Information
- 7.16.2 Acrotech Biopharma Business Overview
- 7.16.3 Acrotech Biopharma Follicular Lymphoma Drugs Revenue and Gross Margin (2021-2026)
- 7.16.4 Acrotech Biopharma Follicular Lymphoma Drugs Product Portfolio
- 7.16.5 Acrotech Biopharma Recent Developments
8 North America
- 8.1 North America Follicular Lymphoma Drugs Revenue (2021-2032)
- 8.2 North America Follicular Lymphoma Drugs Revenue by Type (2021-2032)
- 8.2.1 North America Follicular Lymphoma Drugs Revenue by Type (2021-2026)
- 8.2.2 North America Follicular Lymphoma Drugs Revenue by Type (2027-2032)
- 8.3 North America Follicular Lymphoma Drugs Revenue Share by Type (2021-2032)
- 8.4 North America Follicular Lymphoma Drugs Revenue by Application (2021-2032)
- 8.4.1 North America Follicular Lymphoma Drugs Revenue by Application (2021-2026)
- 8.4.2 North America Follicular Lymphoma Drugs Revenue by Application (2027-2032)
- 8.5 North America Follicular Lymphoma Drugs Revenue Share by Application (2021-2032)
- 8.6 North America Follicular Lymphoma Drugs Revenue by Country
- 8.6.1 North America Follicular Lymphoma Drugs Revenue by Country (2021 VS 2025 VS 2032)
- 8.6.2 North America Follicular Lymphoma Drugs Revenue by Country (2021-2026)
- 8.6.3 North America Follicular Lymphoma Drugs Revenue by Country (2027-2032)
- 8.6.4 United States
- 8.6.5 Canada
9 Europe
- 9.1 Europe Follicular Lymphoma Drugs Revenue (2021-2032)
- 9.2 Europe Follicular Lymphoma Drugs Revenue by Type (2021-2032)
- 9.2.1 Europe Follicular Lymphoma Drugs Revenue by Type (2021-2026)
- 9.2.2 Europe Follicular Lymphoma Drugs Revenue by Type (2027-2032)
- 9.3 Europe Follicular Lymphoma Drugs Revenue Share by Type (2021-2032)
- 9.4 Europe Follicular Lymphoma Drugs Revenue by Application (2021-2032)
- 9.4.1 Europe Follicular Lymphoma Drugs Revenue by Application (2021-2026)
- 9.4.2 Europe Follicular Lymphoma Drugs Revenue by Application (2027-2032)
- 9.5 Europe Follicular Lymphoma Drugs Revenue Share by Application (2021-2032)
- 9.6 Europe Follicular Lymphoma Drugs Revenue by Country
- 9.6.1 Europe Follicular Lymphoma Drugs Revenue by Country (2021 VS 2025 VS 2032)
- 9.6.2 Europe Follicular Lymphoma Drugs Revenue by Country (2021-2026)
- 9.6.3 Europe Follicular Lymphoma Drugs Revenue by Country (2027-2032)
- 9.6.4 Germany
- 9.6.5 France
- 9.6.6 U.K.
- 9.6.7 Italy
- 9.6.8 Netherlands
- 9.6.9 Nordic Countries
10 China
- 10.1 China Follicular Lymphoma Drugs Revenue (2021-2032)
- 10.2 China Follicular Lymphoma Drugs Revenue by Type (2021-2032)
- 10.2.1 China Follicular Lymphoma Drugs Revenue by Type (2021-2026)
- 10.2.2 China Follicular Lymphoma Drugs Revenue by Type (2027-2032)
- 10.3 China Follicular Lymphoma Drugs Revenue Share by Type (2021-2032)
- 10.4 China Follicular Lymphoma Drugs Revenue by Application (2021-2032)
- 10.4.1 China Follicular Lymphoma Drugs Revenue by Application (2021-2026)
- 10.4.2 China Follicular Lymphoma Drugs Revenue by Application (2027-2032)
- 10.5 China Follicular Lymphoma Drugs Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
- 11.1 Asia Follicular Lymphoma Drugs Revenue (2021-2032)
- 11.2 Asia Follicular Lymphoma Drugs Revenue by Type (2021-2032)
- 11.2.1 Asia Follicular Lymphoma Drugs Revenue by Type (2021-2026)
- 11.2.2 Asia Follicular Lymphoma Drugs Revenue by Type (2027-2032)
- 11.3 Asia Follicular Lymphoma Drugs Revenue Share by Type (2021-2032)
- 11.4 Asia Follicular Lymphoma Drugs Revenue by Application (2021-2032)
- 11.4.1 Asia Follicular Lymphoma Drugs Revenue by Application (2021-2026)
- 11.4.2 Asia Follicular Lymphoma Drugs Revenue by Application (2027-2032)
- 11.5 Asia Follicular Lymphoma Drugs Revenue Share by Application (2021-2032)
- 11.6 Asia Follicular Lymphoma Drugs Revenue by Country
- 11.6.1 Asia Follicular Lymphoma Drugs Revenue by Country (2021 VS 2025 VS 2032)
- 11.6.2 Asia Follicular Lymphoma Drugs Revenue by Country (2021-2026)
- 11.6.3 Asia Follicular Lymphoma Drugs Revenue by Country (2027-2032)
- 11.6.4 Japan
- 11.6.5 South Korea
- 11.6.6 India
- 11.6.7 Australia
- 11.6.8 Taiwan
- 11.6.9 Southeast Asia
12 South America, Middle East and Africa
- 12.1 SAMEA Follicular Lymphoma Drugs Revenue (2021-2032)
- 12.2 SAMEA Follicular Lymphoma Drugs Revenue by Type (2021-2032)
- 12.2.1 SAMEA Follicular Lymphoma Drugs Revenue by Type (2021-2026)
- 12.2.2 SAMEA Follicular Lymphoma Drugs Revenue by Type (2027-2032)
- 12.3 SAMEA Follicular Lymphoma Drugs Revenue Share by Type (2021-2032)
- 12.4 SAMEA Follicular Lymphoma Drugs Revenue by Application (2021-2032)
- 12.4.1 SAMEA Follicular Lymphoma Drugs Revenue by Application (2021-2026)
- 12.4.2 SAMEA Follicular Lymphoma Drugs Revenue by Application (2027-2032)
- 12.5 SAMEA Follicular Lymphoma Drugs Revenue Share by Application (2021-2032)
- 12.6 SAMEA Follicular Lymphoma Drugs Revenue by Country
- 12.6.1 SAMEA Follicular Lymphoma Drugs Revenue by Country (2021 VS 2025 VS 2032)
- 12.6.2 SAMEA Follicular Lymphoma Drugs Revenue by Country (2021-2026)
- 12.6.3 SAMEA Follicular Lymphoma Drugs Revenue by Country (2027-2032)
- 12.6.4 Brazil
- 12.6.5 Argentina
- 12.6.6 Chile
- 12.6.7 Colombia
- 12.6.8 Peru
- 12.6.9 Saudi Arabia
- 12.6.10 Israel
- 12.6.11 UAE
- 12.6.12 Turkey
- 12.6.13 Iran
- 12.6.14 Egypt
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst